SCHEDULE: FMR LLC Reports 3.2% Stake in Moderna Inc.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 3.2% beneficial ownership stake in Moderna Inc., totaling 12,304,297.37 shares as of September 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson beneficially own 12,304,297.37 shares of Moderna Inc. common stock.
• This ownership represents 3.2% of Moderna's total outstanding common stock.
• The event date requiring this Schedule 13G filing was September 30, 2025.
• FMR LLC holds sole voting power over 12,235,058.95 shares and sole dispositive power over 12,304,297.37 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is also deemed to beneficially own the same 12,304,297.37 shares with sole dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Moderna Inc.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor, providing factual information without expressing a positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• FMR LLC, a major institutional investor, maintains a significant beneficial ownership stake in Moderna Inc., indicating continued institutional interest.
• The filing confirms a substantial investment by FMR LLC and its affiliates, holding 12,304,297.37 shares.

Future Outlook

This filing is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding Moderna Inc.'s future outlook.

Management Comments

• The securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing represents a routine disclosure of an institutional investor's stake in a publicly traded biotechnology company. It reflects FMR LLC's ongoing investment position in Moderna Inc., a prominent player in the pharmaceutical and vaccine development sector.

Comparison to Industry Standards

• Not applicable as this Schedule 13G filing reports beneficial ownership and does not contain financial or operational results for comparison to industry standards or specific comparable companies.

Corporate Governance

Related Party Transactions

• Abigail P. Johnson is a Director, the Chairman, and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. They have a shareholders' voting agreement to vote all Series B shares in accordance with the majority vote.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings in Moderna Inc.
• Investors: Indicates continued institutional interest in Moderna Inc. by a major asset manager.

Key Dates

Keywords

Moderna, MRNA, FMR LLC, Abigail P. Johnson, beneficial ownership, Schedule 13G, institutional investment, common stock